Celastrol inhibits the secretion of interleukin-17 in peripheral blood mononuclear cells in patients with sympathetic ophthalmia_Chinese Journal of Ocular Fundus Diseases

Authors：

Qin Tingyu ,  Gao Shasha , Wang Wenzhan

Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China;

Corresponding author：

Gao Shasha, Email: shashag@126.com

Keywords：

Ophthalmia, sympathetic/drug therapy; Tripterygium; Interleukin-17; Interleukin-23

DOI：

10.3760/cma.j.issn.1005-1015.2018.01.013

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To observe the effect of celastrol on the secretion of interleukin (IL)-17 in peripheral blood mononuclear cells in patients with sympathetic ophthalmia (SO), and its possible mechanisms. Methods Venous blood samples were extracted from 10 cases of sympathetic ophthalmia patients and 10 health objectives. The peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation and then were divided into 4 groups. Group A (control group): PBMCs of health objectives; Group B: PBMCs of SO patients; Group C: PBMCs of SO patients with 0.5 μmol/L celastrol in the medium; Group D: PBMCs of SO patients with 1 μmol/L celastrol in the medium. After culturing the cells for 3 days, the supernatant of 4 groups was collected, and the levels of IL-23 and IL-17 were detected by enzyme-linked immuno sorbent assay (ELISA). Then, the 50 ng/ml rIL-23 was added into the medium of group A which was the group A1; the 50ng/ml rIL-23 and 1 μmol/L Cela were added into to the medium of group A which was the group A2. For the medium of group B, the 50 ng/ml rIL-23 was added into the medium which was the group B1; the 50 ng/ml rIL-23 and 1 μmol/L celastrol were added into to the medium of group B which was the group B2. After culturing for 3 days, the supernatant of cells of these 4 groups was collected, and the levels of IL-17 were detected by ELISA. Results In group A, the levels of IL-23 and IL-17 were (228.43±17.27) pg/ml and (220.55±31.15) pg/ml respectively. In group B, the levels of IL-23 and IL-17 were (513.85±36.46) pg/ml and (866.77±72.92) pg/ml respectively. In group C, the levels of IL-23 and IL-17 were (381.07±20.93) pg/ml and (517.43±54.87) pg/ml respectively. In group D, the levels of IL-23 and IL-17 were (237.14±17.97) pg/ml and (242.89±34.09) pg/ml respectively. Between group A and D, there was no statistically significant difference in IL-23 or IL-17 level (P＞0.05); but when comparing other groups, the differences were statistically significant (P＜0.05). The levels of IL-17 in group A1 and group A2 were (428.43±24.53) pg/ml and (229.15±23.28) pg/ml and the difference was statistically significant (P＜0.05). The levels of IL-17 in group B1 and group B2 were (1373.39±89.51) pg/ml and (571.01±94.88) pg/ml and the difference was statistically significant (P＜0.05). Conclusion Celastrol can inhibit the secretion of IL-17 by PBMCs in SO patients via inhibiting the secretion of IL-23.

Citation： Qin Tingyu, Gao Shasha, Wang Wenzhan. Celastrol inhibits the secretion of interleukin-17 in peripheral blood mononuclear cells in patients with sympathetic ophthalmia. Chinese Journal of Ocular Fundus Diseases, 2018, 34(1): 51-54. doi: 10.3760/cma.j.issn.1005-1015.2018.01.013 Copy

1.	Chaithanyaa N, Devireddy SK, Kishore Kumar RV, et al. Sympathetic ophthalmia: a review of literature [J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2012, 113(2): 172-176. DOI: 10.1016/j.tripleo.2011.01.036.
2.	张锐, 钱江, 袁一飞. 交感性眼炎患者房水和血清细胞因子水平的分析 [J]. 中国眼耳鼻喉科杂志, 2014, 14(1): 17-20.Zhang R, Qian J, Yuan YF. Cytokine analysis in the aqueous humor and serum of patients with sympathetic ophthalmia [J]. Chin J Ophthalmol and Otorhinolaryngol, 2014, 14(1): 17-20.
3.	Furusato E, Shen D, Cao X, et al. Inflammatory cytokine and chemokine expression in sympathetic ophthalmia: a pilot study [J]. Histol Histopathol, 2011, 26(9): 1145-1151. DOI: 10.14670/HH-26.1145.
4.	施沛青, 朱书, 钱友存. IL-17的信号传导及功能研究 [J]. 中国细胞生物学学报, 2011, 33(4): 345-357.Shi PQ, Zhu S, Qian YC. IL-17 signaling and function [J]. Chin J of Cell Bio, 2011, 33(4): 345-357.
5.	Bettelli E, Korn T, Oukka M, et al. Induction and effector functions of T(H)17 cells [J]. Nature, 2008, 453(7198): 1051-1057. DOI: 10.1038/nature07036.
6.	李婷, 孙万邦. 眼外伤患者血清Th亚群细胞因子变化的临床意义 [J]. 中华眼外伤职业眼病杂志, 2016, 38(7): 494-497. DOI: 10.3760/cma.j.issn.2095-1477.2016.07.004.Li T, Sun WB. The clinical significance of the changes of Th subgroup cytokines in patients with ocular trauma [J]. Chin J Ocul Traum Occupat Eye Dis, 2016, 38(7): 494-497. DOI: 10.3760/cma.j.issn.2095-1477.2016.07.004.
7.	Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells [J]. Immunity, 2006, 24(2): 179-189. DOI: 10.1016/j.immuni.2006.01.001.
8.	Bettelli E, Kuchroo VK. IL-12- and IL-23-induced T helper cell subsets: birds of the same feather flock together [J]. J Exp Med, 2005, 201(2): 169-171. DOI: 10.1084/jem.20042279.
9.	Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 [J]. J Biol Chem, 2003, 278(3): 1910-1914. DOI: 10.1074/jbc.M207577200.
10.	McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway [J]. Trends Immunol, 2006, 27(1): 17-23. DOI: 10.1016/j.it.2005.10.003.
11.	陈建华. 炎症性肠病患者血清IL-23, IL-17, IL-25含量及临床意义 [J]. 中华临床医师杂志, 2012, 6(3): 698-699. DOI: 10.3877/cma.j.issn.1674-0785.2012.03.040.Chen JH. Serum IL-23, IL-17, IL-25 content and these clinical significance in patients with inflammatory bowel disease [J]. Chin J Clinicians, 2012, 6(3): 698-699. DOI: 10.3877/cma.j.issn.1674-0785.2012.03.040.
12.	Chi W, Yang P, Li B, et al. IL-23 promotes CD4⁺ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease [J]. J Allergy Clin Immunol, 2007, 119(5): 1218-1224. DOI: 10.1016/j.jaci.2007.01.010.
13.	Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis [J]. Invest Ophthalmol Vis Sci, 2008, 49(7): 3058-3064. DOI: 10.1167/iovs.07-1390.
14.	赵莹莲. 雷公藤红素作用机制的研究进展 [J]. 临床合理用药, 2015, 8(9): 170-171. DOI: 10.15887/j.cnki.13-1389/r.2015.26.124.Zhao YL. Research progress of the effect mechanism of tripterine [J]. Chin J of Clinical Rational Drug Use, 2015, 8(9): 170-171. DOI: 10.15887/j.cnki.13-1389/r.2015.26.124.
15.	罗丽娟, 张荷珍, 韩英军. 交感性眼炎的临床分析 [J]. 中华眼外伤职业眼病杂志, 2013, 35(4): 289-291. DOI: 10.3760/cma.j.issn. 2095-1477.2013.04.017.Luo LJ, Zhang HZ, Han YJ. Clinical analysis of sympathetic ophthalmia [J]. Chin J Ocul Traum Occupat Eye Dis, 2013, 35(4): 289-291. DOI: 10.3760/cma.j.issn. 2095-1477.2013.04.017.
16.	白雪莲. 33例多种交感性眼炎的临床诊断及治疗 [J]. 中国现代医生, 2009, 47(22): 128, 134. DOI: 10.3969/j.issn.1673-9701.2009.22.077.Bai XL. The clinical diagnosis and treatment of 33 cases of sympathetic ophthalmia. Chin Modern Doctor, 2009, 47(22): 128, 134. DOI: 10.3969/j.issn.1673-9701.2009.22.077.
17.	夏玲红, 崔岚. 雷公藤红素的药理作用研究进展 [J]. 医药导报, 2009, 28(6): 730-732. DOI: 10.3870/yydb.2009.06.020.Xia LH, Cui L. Research progress on pharmacological action of celastrol [J]. Herald of Medic, 2009, 28(6): 730-732. DOI: 10.3870/yydb.2009.06.020.

1. Chaithanyaa N, Devireddy SK, Kishore Kumar RV, et al. Sympathetic ophthalmia: a review of literature [J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2012, 113(2): 172-176. DOI: 10.1016/j.tripleo.2011.01.036.
2. 张锐, 钱江, 袁一飞. 交感性眼炎患者房水和血清细胞因子水平的分析 [J]. 中国眼耳鼻喉科杂志, 2014, 14(1): 17-20.Zhang R, Qian J, Yuan YF. Cytokine analysis in the aqueous humor and serum of patients with sympathetic ophthalmia [J]. Chin J Ophthalmol and Otorhinolaryngol, 2014, 14(1): 17-20.
3. Furusato E, Shen D, Cao X, et al. Inflammatory cytokine and chemokine expression in sympathetic ophthalmia: a pilot study [J]. Histol Histopathol, 2011, 26(9): 1145-1151. DOI: 10.14670/HH-26.1145.
4. 施沛青, 朱书, 钱友存. IL-17的信号传导及功能研究 [J]. 中国细胞生物学学报, 2011, 33(4): 345-357.Shi PQ, Zhu S, Qian YC. IL-17 signaling and function [J]. Chin J of Cell Bio, 2011, 33(4): 345-357.
5. Bettelli E, Korn T, Oukka M, et al. Induction and effector functions of T(H)17 cells [J]. Nature, 2008, 453(7198): 1051-1057. DOI: 10.1038/nature07036.
6. 李婷, 孙万邦. 眼外伤患者血清Th亚群细胞因子变化的临床意义 [J]. 中华眼外伤职业眼病杂志, 2016, 38(7): 494-497. DOI: 10.3760/cma.j.issn.2095-1477.2016.07.004.Li T, Sun WB. The clinical significance of the changes of Th subgroup cytokines in patients with ocular trauma [J]. Chin J Ocul Traum Occupat Eye Dis, 2016, 38(7): 494-497. DOI: 10.3760/cma.j.issn.2095-1477.2016.07.004.
7. Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells [J]. Immunity, 2006, 24(2): 179-189. DOI: 10.1016/j.immuni.2006.01.001.
8. Bettelli E, Kuchroo VK. IL-12- and IL-23-induced T helper cell subsets: birds of the same feather flock together [J]. J Exp Med, 2005, 201(2): 169-171. DOI: 10.1084/jem.20042279.
9. Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 [J]. J Biol Chem, 2003, 278(3): 1910-1914. DOI: 10.1074/jbc.M207577200.
10. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway [J]. Trends Immunol, 2006, 27(1): 17-23. DOI: 10.1016/j.it.2005.10.003.
11. 陈建华. 炎症性肠病患者血清IL-23, IL-17, IL-25含量及临床意义 [J]. 中华临床医师杂志, 2012, 6(3): 698-699. DOI: 10.3877/cma.j.issn.1674-0785.2012.03.040.Chen JH. Serum IL-23, IL-17, IL-25 content and these clinical significance in patients with inflammatory bowel disease [J]. Chin J Clinicians, 2012, 6(3): 698-699. DOI: 10.3877/cma.j.issn.1674-0785.2012.03.040.
12. Chi W, Yang P, Li B, et al. IL-23 promotes CD4⁺ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease [J]. J Allergy Clin Immunol, 2007, 119(5): 1218-1224. DOI: 10.1016/j.jaci.2007.01.010.
13. Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis [J]. Invest Ophthalmol Vis Sci, 2008, 49(7): 3058-3064. DOI: 10.1167/iovs.07-1390.
14. 赵莹莲. 雷公藤红素作用机制的研究进展 [J]. 临床合理用药, 2015, 8(9): 170-171. DOI: 10.15887/j.cnki.13-1389/r.2015.26.124.Zhao YL. Research progress of the effect mechanism of tripterine [J]. Chin J of Clinical Rational Drug Use, 2015, 8(9): 170-171. DOI: 10.15887/j.cnki.13-1389/r.2015.26.124.
15. 罗丽娟, 张荷珍, 韩英军. 交感性眼炎的临床分析 [J]. 中华眼外伤职业眼病杂志, 2013, 35(4): 289-291. DOI: 10.3760/cma.j.issn. 2095-1477.2013.04.017.Luo LJ, Zhang HZ, Han YJ. Clinical analysis of sympathetic ophthalmia [J]. Chin J Ocul Traum Occupat Eye Dis, 2013, 35(4): 289-291. DOI: 10.3760/cma.j.issn. 2095-1477.2013.04.017.
16. 白雪莲. 33例多种交感性眼炎的临床诊断及治疗 [J]. 中国现代医生, 2009, 47(22): 128, 134. DOI: 10.3969/j.issn.1673-9701.2009.22.077.Bai XL. The clinical diagnosis and treatment of 33 cases of sympathetic ophthalmia. Chin Modern Doctor, 2009, 47(22): 128, 134. DOI: 10.3969/j.issn.1673-9701.2009.22.077.
17. 夏玲红, 崔岚. 雷公藤红素的药理作用研究进展 [J]. 医药导报, 2009, 28(6): 730-732. DOI: 10.3870/yydb.2009.06.020.Xia LH, Cui L. Research progress on pharmacological action of celastrol [J]. Herald of Medic, 2009, 28(6): 730-732. DOI: 10.3870/yydb.2009.06.020.

Chinese Journal of Ocular Fundus Diseases

Celastrol inhibits the secretion of interleukin-17 in peripheral blood mononuclear cells in patients with sympathetic ophthalmia

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content